Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.41 |
| ▸ | CA2 | P00918 | 2/20 | 0.40 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | ESR2 | Q92731 | 1/20 | 0.39 |
| ▸ | ADRA1D | P25100 | 5/20 | 0.36 |
| ▸ | ADRA1A | P35348 | 5/20 | 0.36 |
| ▸ | ADRA1B | P35368 | 5/20 | 0.36 |
| ▸ | DRD2 | P14416 | 1/20 | 0.35 |
| ▸ | HTR2A | P28223 | 1/20 | 0.35 |
| ▸ | SLC6A4 | P31645 | 1/20 | 0.35 |
| ▸ | HTR2B | P41595 | 1/20 | 0.35 |
| ▸ | HTR1A | P08908 | 2/20 | 0.34 |
| ▸ | HTR1D | P28221 | 1/20 | 0.34 |
| ▸ | HTR7 | P34969 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1875160 | 0.89 | POLB (0.46) | SMN1; SMN2ALDH1A1CA2POLBESR2 | |
| SCHEMBL1042558 | 0.86 | CA2 (0.41) | SMN1; SMN2ALDH1A1CA2POLBESR2 | |
| SCHEMBL1873324 | 0.86 | POLB (0.54) | SMN1; SMN2ALDH1A1CA2POLBESR2 | |
| SCHEMBL1879143 | 0.83 | CA2 (0.42) | SMN1; SMN2ALDH1A1CA2POLBESR2 | |
| SCHEMBL1083037 | 0.82 | ADRA1D (0.46) | ALDH1A1ADRA1DADRA1AADRA1BHTR1A | |
| SCHEMBL1876054 | 0.80 | CA2 (0.44) | ALDH1A1CA2POLBESR2ADRA1D | |
| SCHEMBL1081154 | 0.80 | CA2 (0.40) | CA2POLBESR2ADRA1DADRA1A | |
| SCHEMBL1880014 | 0.80 | CA2 (0.40) | SMN1; SMN2ALDH1A1CA2POLBESR2 | |
| SCHEMBL1870566 | 0.76 | CA2 (0.41) | SMN1; SMN2ALDH1A1CA2POLBESR2 | |
| SCHEMBL15864983 | 0.75 | HTR1A (0.40) | CA2DRD2HTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | claimed |
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | NSAB, FILIAL AF NEUROSEARCH SWEDEN AB, SVERIGE (DK) | 2011-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110105462-A1 | MODULATORS OF DOPAMINE NEUROTRANSMISSION | DBH, SLC18A2, SLC6A3 | SMN1; SMN2 689/4885ALDH1A1 1056/4885CA2 3728/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.